ISRCTN13102817CompletedUnknown
Early Access experience with burosumab in adults with X-linked hypophosphataemia in the UK: real-world clinical and patient-reported outcomes
Kyowa Kirin International (United Kingdom)0 sites142 target enrollmentStarted: August 1, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Completed
- Sponsor
- Enrollment
- 142
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •All participants enrolled in the burosumab early access programme (EAP) will be considered for inclusion
Exclusion Criteria
- •Participants opting out will not have their clinical data collected
Investigators
Similar Trials
Completed
Phase 3
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)X-linked HypophosphatemiaNCT02526160Kyowa Kirin, Inc.134
Active, not recruiting
Phase 1
A sing le-arm, phase I study of ramucirumab in combination with erlotinib or osimertinib in previously untreated patients with EGFR mutantion-posit ive metastatic Non-small cell lung cancer with brain metastaseslung carcinoma, non small cellD002289JPRN-jRCT2051190027Kaneda Hiroyasu6
Recruiting
Unknown
Efficacy of brolucizumab for age-related macular degeneratioJPRN-UMIN000050137Kawasaki Medical School100
Recruiting
Phase 2
Phase II study of ramucirumab for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190083Yamashita Tatsuya33
Completed
Phase 1
BUBBLE: Buparlisib with bortezomib in relapsed or refractory multiple myelomaTopic: CancerSubtopic: Haematological OncologyDisease: MyelomaCancerISRCTN22287432niversity of Birmingham (UK)60